- Top 4 Big Data Analytics Strategies to Reduce Hospital Readmissions
“We at Roswell are excited to join CancerLinQ,” said Stephen Edge, MD, FACS, FASCO, Vice President of Healthcare Outcomes and Policy at Roswell Park. “We hope to use it to enhance our quality oversight, benchmark care, use with other data to better understand care delivery and quality, and support local and national research efforts.”
CancerLinQ collects and analyzes real-world cancer data from multiple healthcare IT systems to improve the quality of care and care operations. As a non-profit subsidiary of the American Society of Clinical Oncology (ASCO), CancerLinQ is the only non-profit, physician-led big data analytics platform for cancer in the US. CancerLinQ reflects the unique experiences of a broad range of cancer patients, allowing clinicians to generate meaningful insights about the disease.
Sixty practices have completed the onboarding process to establish a link between the CancerLinQ database and their EHR system, and more than 1.5 million de-identified, real-world patient cancer records are now in the database. CancerLinQ is now helping these practices improve patient care through quality automation tools, as well as dashboards and reports that provide actionable insights.
“The CancerLinQ database reflects cancer care in all its real-world variability, including practice settings, communities, and age of patients being treated,” said CancerLinQ CEO Cory Wiegert. “Practices who participate are able to access a platform that enables them to meet quality reporting requirements in a more seamless fashion and discover insights that can improve the care they provide.”
CancerLinQ has previously partnered with key federal agencies to gather more data on diverse cohorts of patients, offering providers a picture of different types of cancer.
In 2017, the organization announced a collaboration with the National Cancer Institute (NCI) and the FDA to allow for deeper big data insights. The partnerships provided NCI and FDA with a wealth of real-world information to open up new possibilities for gathering important insights, enhancing research, and generating better outcomes for patients.
“We want to make sure that society is able to benefit from the knowledge that is often hidden away in EHRs and lab reports and never included in clinical trials. And we want to make sure that regulators can do their jobs as well as possible when it comes to labeling and making recommendations,” Clifford A. Hudis, MD, FACP, FASCO, Chairman of the Board of Governors for CancerLinQ, told HealthITAnalytics.com.
“The more knowledge we have as a health system, the more we will be able to provide the highest quality care to patients who often have very few other options.”
By Jessica Kent